The stock’s latest move extends a broader rally, with the share price gaining 22% over the past month. Verkazia functions as a calcineurin inhibitor immunomodulator, designed to address the root causes of eye inflammation. While the drug offers a steroid-sparing alternative for patients, it carries clinical warnings regarding potential side effects, specifically the formation of cataracts and glaucoma.

Chief Executive Mark Baum signaled that the company’s primary objective for this rollout is to stabilize the supply chain and simplify patient access. By removing hurdles for physicians, Harrow aims to establish a more reliable delivery model for the medication. The company is positioning the relaunch as a pivot toward consistent availability, prioritizing long-term management of the chronic disease over temporary, reactive fixes.